Peptides 101: What's FDA-Approved, What's Experimental, and What to Ask Your Doctor

Peptide therapy is one of the fastest-growing conversations in medicine right now — and one of the most confusing. In the same breath, patients ask me about Ozempic, BPC-157 vials they saw on Instagram, and "growth hormone peptides" from a longevity clinic. They are not the same thing, and treating them the same is exactly how people get hurt.

As an Internal Medicine physician, I want to walk you through what a peptide actually is, which ones have real FDA approval and clinical trial data behind them, which ones are still experimental "research chemicals," and why the rules around all of this are shifting again in 2026.

What Exactly Is a "Peptide," Anyway?

A peptide is simply a short chain of amino acids — the same building blocks that make up every protein in your body. Your body already makes thousands of peptides naturally, including insulin and growth hormone-releasing hormone. "Peptide therapy" has become a catch-all marketing term that now covers everything from rigorously tested prescription drugs to unregulated vials shipped in the mail, and that blur is the source of most of the confusion I see in my practice.

• Peptides are just short protein fragments — some made by your body, some synthetic copies or modifications of them.

• Not every peptide is manufactured, tested, or regulated the same way.

• "Peptide" as a marketing label doesn't tell you anything about safety or evidence on its own.

The Peptides With Real FDA Approval and Data Behind Them

Semaglutide and tirzepatide — the GLP-1 and GLP-1/GIP receptor agonists behind Ozempic, Wegovy, Mounjaro, and Zepbound — are technically peptide drugs, and they're the best-studied ones on the market. They went through large randomized controlled trials before approval, and they continue to be studied for cardiovascular and metabolic outcomes.

• Semaglutide was approved for chronic weight management in 2021; tirzepatide followed in 2023.

• Both are backed by large, published clinical trials, not just patient testimonials.

• Approved doesn't mean risk-free — GI side effects are common, and rare but serious risks like pancreatitis exist.

The "Research Chemical" Peptides Everyone's Talking About

BPC-157 and TB-500 have exploded in popularity for injury recovery, gut healing, and general "biohacking," largely on the strength of rodent and cell-culture studies rather than large human trials. Current peer-reviewed literature has not shown that BPC-157 causes cancer, but its mechanism promotes blood vessel growth (angiogenesis), which is a theoretical concern if a patient already has an undiagnosed tumor. No prospective human study has tracked long-term users to settle the question either way.

• Marketed for tendon, ligament, and gut repair, based mainly on animal data — not large human trials.

• The concern isn't that it causes cancer; it's the unproven theoretical risk that it could accelerate an existing one.

• Products sold online as "research chemicals" are not held to pharmaceutical manufacturing or purity standards, and independent testing has repeatedly found dosing and purity problems.

Growth Hormone Peptides and the Anti-Aging Pitch

CJC-1295 and ipamorelin are marketed heavily in longevity clinics and med spas for muscle gain, fat loss, better sleep, and anti-aging. Neither is FDA-approved for any medical use. The FDA has specifically flagged safety signals for these growth hormone secretagogues, including immunogenic reactions, elevated heart rate, and vasodilatory responses, while noting that available clinical data remains limited.

• These work by stimulating your own pituitary gland to release more growth hormone — they are not growth hormone itself.

• The FDA has identified real safety signals, including allergic-type reactions and cardiovascular effects.

• They are distributed as unapproved research compounds, not as regulated pharmaceutical products.

Why the Rules Are Changing Right Now

In 2023, the FDA placed BPC-157 and several similar peptides on a list of substances considered too risky for compounding pharmacies to dispense. In July 2026, the FDA's Pharmacy Compounding Advisory Committee met to reconsider that decision for BPC-157, KPV, and other peptides. This matters for patients, but it's easy to misread: removing a peptide from the restricted list is a separate step from full FDA drug approval. It would make a peptide easier to obtain through a licensed compounding pharmacy — it does not mean the FDA has verified it is safe and effective for a specific use.

• 2023: the FDA restricted BPC-157 and similar peptides from routine compounding.

• 2026: the same advisory committee is reconsidering broader, physician-directed access.

• Looser compounding rules are not the same thing as FDA approval — the evidence bar hasn't changed, only the access question has.

How to Approach Peptide Therapy Safely

The peptide conversation isn't going away, and some of these compounds may genuinely earn a place in mainstream care over time. Until then, the safest path is the same one I'd recommend for any new treatment: real evaluation, real monitoring, and an honest conversation about what is proven versus what is promising.

• Get real bloodwork, a real diagnosis, and physician monitoring — not just a menu at a spa kiosk.

• Ask directly: is this peptide FDA-approved for my condition, or is it compounded/research-grade?

• Disclose any personal or family history of cancer before starting anything with tissue-growth or angiogenic effects.

The Bottom Line

Peptide therapy is exploding in popularity, but "peptide" is not a safety guarantee — it's a chemical category that includes some of the best-studied drugs in modern medicine alongside compounds with almost no human safety data at all. Sort by evidence, not by hype, and loop in a physician who will actually look at your labs and your history before recommending anything.

This content is for general educational purposes only and is not a substitute for professional medical advice. Always consult your physician before starting, stopping, or changing any medication or supplement, including peptide therapies.

Sources cited

• U.S. Food and Drug Administration. "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss." fda.gov.

• U.S. Food and Drug Administration. "July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee." fda.gov.

• Józwiak, M. et al. "Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review." Pharmaceuticals, 2025;18(2):185. PMC11859134.

• "Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives." International Journal of Molecular Sciences, 2026;27(9):3890.

• "Compare and Contrast the Glucagon-Like Peptide-1 Receptor Agonists (GLP1RAs)." StatPearls, NCBI Bookshelf. NBK572151.